Global Brain Biomarkers Market

Brain Biomarkers Market size was valued at US$ 7.76 Bn in 2022 and the total revenue is expected to grow at CAGR 12.9% through 2023 to 2029, reaching nearly US$ 18.16 Bn

Brain Biomarkers Market Overview:

Biomarkers provide detailed measure of abnormal changes in the brain, which can detect in early possible disease in people with mild symptoms. People with Alzheimer's disease and related dementias progress at different rates, and biomarkers may help predict and monitor their progression. Brain Biomarkers is related to electroplating which is the production of thin surface coating of metal upon another by electro deposition.AS increasing the brain disease like Alzheimer's and Dementia in the people these factor contributing to the growth of Brain Biomarkers Market. Rising geriatric population is also the primary factor for the growth of Brain Biomarkers Market.

To know about the Research Methodology :- Request Free Sample Report

Brain Biomarkers Market Dynamics:

The Increasing prevalence of different brain disease is driving the growth of brain biological market. The market growth can be attributed to rise in the prevalence of neurological disease such as Migraines, Dementia, Alzheimer's disease, brain tumour and Epilepsy. Increasing cases of Alzheimer's in the older age people are expected to fuel the market growth. According to WHO, approximately 50 Million people have dementia and 10 Mn new cases are registered daily.

According to Alzheimer association 13.8 Mn people above age 50 are estimated to suffer from Alzheimer, Dementia by the end of 2029. Technological advancement and innovation in the diagnosis and treatment are also0 contributing to the growth of Brain Biomarkers Market. Validating biomarkers are the lengthy process inconsistency in its performance in disease diagnosis. Because of this validation process is time consuming as well as expensive. Extensive clinical validation, these are the factors which restraint the market growth.

The recent development in biomarker signature are making neurological disease more treatable. This resulted faster drug development and non-invasive testing. Digital biomarkers provide various pharmaceutical companies with contextual and supplemental information to conclude clinical trial decisions. Personalised medicine is used to identify the beneficial treatment path for the individual patients. The use of biomarker play the important role in the certain aspect of personalised medicine. Consumables used in biomarker testing enable the identification of these diseases. Biomarker diagnostic products are also used as companion diagnostics for several investigational therapies. For example, as per the report of World Bank, the global healthcare spending increased at CAGR 9.8% from 2017 to 2022.

Brain Biomarkers Market Segment Analysis:

The Brain Biomarkers Market is segmented by Product type, by Application

Based on the Product type, The Brain Biomarkers Market is segmented into the Genomic, Proteomic, Metabolomics, Imaging, Others. Proteomic segment is dominated the Brain Biomarkers Market with highest market share of 37% in the year 2022. Genomic segment is accounted for the second largest segment in the year 2022. Genomic biomarkers present promising opportunities for the development of personalized medicines and diagnostics based on an individual’s specific genetic variations & predisposition to the disease. The method used for the detecting presence and studying genomic biomarker for the identification disease include Comparative Genomic Hybridization (CGH),gene expression profiling Single Nucleotide Polymorphisms (SNPs), and whole-genome sequencing.

Based on the Application, The Brain Biomarkers Market is segmented into the Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis, and Autism Spectrum Disorders. Alzheimer’s disease application segment held the largest market share of xx% in the year 2022.This segment is expected to grow at CAGR 13.2% during the forecast period. This growth is because of availability of product for clinical use, such as imaging biomarkers-amyloid PET tracers for diagnosis. Parkinson’s disease application segment is expected to grow at higher CAGR of 13.2% during the forecast period. Owing to growing prevalence of neurological disease and increasing number of clinical trial for the disease drug.

Based on the End User, The Brain Biomarkers Market is segmented into the Hospital Laboratories, Independent Clinical Diagnostic Centers, Research Organizations, Other. Hospital Laboratories segment held the largest market share of 38% in the year 2022.This segment is expected to remain dominant even during the forecasting period. Because of rise in the healthcare infrastructure and development in the technology. This factor attributing to the growth of Brain Biomarkers Market. Research Organizations segment expected to grow at CAGR more than 13% during the forecasting period.

Brain Biomarkers Market Regional Insights:

North America dominated the Brain Biomarkers Market with the largest market share of 41.9% in 2022.It is also expected to register at CAGR of 4.3% during the forecast period. Increase in prevalence of neurological disease and increasing geriatric population, because this disease mostly occur in the old age people. The significantly high disease burden, acceptance of biomarkers for diagnostic, drug development & prognostic purposes, and increase in research funding are some key factors contributing to the dominance of the region.

Increasing product launches with rise in demand for biomarkers are expected to have a positive impact on the regional market. Asia pacific expected to grow the fastest CAGR of 13.6% during the forecast period. An increasing number of clinical trials being conducted in developing countries, such as India and China, rising disease burden, and growing need for targeted drugs in the central nervous system are factors expected to drive the regional market growth.

Furthermore, increased demand of the ageing population for the detection and treatment of age-related disorders, the biomarkers market is dominated by the leading players in the well-established pharmaceuticals sector. According to the survey, around 1.2 million people in the United States are diagnosed with neurological illnesses each year. Furthermore, the biomarkers market in North America is growing due to a higher acceptance rate of biomarkers for illness diagnosis.

The objective of the report is to present a comprehensive analysis of the Brain Biomarkers Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The reports also helps in understanding the Brain Biomarkers Market dynamic, structure by analyzing the market segments and project the Brain Biomarkers Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Brain Biomarkers Market make the report investor’s guide.

Brain Biomarkers Market Scope: Inquire before buying

Brain Biomarkers Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina, Columbia and Rest of South America)

Brain Biomarkers Market, Key Players are

1. Abbott Laboratories
2. Thermo Fisher Scientific, Inc.
3. Bio-Rad Laboratories, Inc.
4. Merck & Co., Inc.
5. Johnson & Johnson Services, Inc.
6. Banyan Biomarkers, Inc.
7. Myriad Genetics, Inc.
8. DiaGenic ASA
9. Quanterix
10. Merck KGaA
11. Enzo Biochem, Inc.
12. Charles River Laboratories International,
13. Eurofins Scientific (Luxembourg).

Frequently Asked Questions:

1] Which segments are covered in Brain Biomarkers Market report?
Ans. The segments covered in Brain Biomarkers Market report are based on by Product Type, by Application & End user

2] Which region is expected to hold the highest share in the Brain Biomarkers Market?
Ans. North America is expected to hold the highest share in the Gynaecological Dilators Market.

3] What is the market size of Brain Biomarkers Market by 2029?
Ans. The market size of Brain Biomarkers Market by 2029 is US $ 18.16 Bn.

4] Who are the top key players in the Brain Biomarkers Market?
Ans. Abbott Laboratories, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Merck & Co., Inc., Johnson & Johnson Services, Inc., Banyan Biomarkers, Inc.,Myriad Genetics, Inc., DiaGenic ASA, Quanterix , Merck KGaA

5] What was the market size of Brain Biomarkers Market in 2022?
Ans. The market size of Brain Biomarkers Market in 2022 was US $ 7.76 Bn.